ECSP19082194A - Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas - Google Patents

Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas

Info

Publication number
ECSP19082194A
ECSP19082194A ECSENADI201982194A ECDI201982194A ECSP19082194A EC SP19082194 A ECSP19082194 A EC SP19082194A EC SENADI201982194 A ECSENADI201982194 A EC SENADI201982194A EC DI201982194 A ECDI201982194 A EC DI201982194A EC SP19082194 A ECSP19082194 A EC SP19082194A
Authority
EC
Ecuador
Prior art keywords
stem cells
antimitoskines
cancer stem
antimitoscinas
specific inhibitors
Prior art date
Application number
ECSENADI201982194A
Other languages
English (en)
Inventor
Federica Sotgia
Michael Lisanti
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of ECSP19082194A publication Critical patent/ECSP19082194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los antibióticos que tienen propiedades anti-mitocondriales intrínsecas se pueden modificar químicamente para dirigir los antibióticos a las mitocondrias, y las "antimitoscinas" resultantes pueden tener propiedades anticancerosas mejoradas, entre otras propiedades ventajosas. También se describen métodos para identificar antimitoscinas, métodos para usar antimitoscinas para fijar como objetivo células madre cancerosas y composiciones farmacéuticas para tratar el cáncer que contienen una o más antimitoscinas como el ingrediente activo. También se dan a conocer compuestos específicos de antimitoscinas y grupos de antimitoscinas.
ECSENADI201982194A 2017-05-19 2019-11-19 Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas ECSP19082194A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508702P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
ECSP19082194A true ECSP19082194A (es) 2019-11-30

Family

ID=64274780

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201982194A ECSP19082194A (es) 2017-05-19 2019-11-19 Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas

Country Status (21)

Country Link
US (2) US11160821B2 (es)
EP (1) EP3624840A4 (es)
JP (1) JP6938682B2 (es)
KR (1) KR20200010343A (es)
CN (1) CN111315400A (es)
AU (1) AU2018270129B2 (es)
BR (1) BR112019024264A2 (es)
CA (1) CA3063717C (es)
CL (1) CL2019003283A1 (es)
CO (1) CO2019012888A2 (es)
CR (1) CR20190524A (es)
CU (1) CU20190092A7 (es)
DO (1) DOP2019000294A (es)
EC (1) ECSP19082194A (es)
IL (1) IL270598B (es)
MX (1) MX2019013735A (es)
PE (1) PE20200605A1 (es)
PH (1) PH12019502594A1 (es)
RU (1) RU2019142102A (es)
WO (1) WO2018213751A1 (es)
ZA (3) ZA201907654B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
CA3078791A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
CA3083487A1 (en) * 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
EP3810284A4 (en) 2018-06-01 2022-06-15 Lunella Biotech, Inc. BIOMARKERS AND THERAPEUTICS IN RESISTANCE TO ENDOCRINE THERAPY
CU24717B1 (es) 2018-10-02 2024-08-15 Lunella Biotech Inc Derivados de azitromicina y roxitromicina como fármacos senolíticos
PE20211551A1 (es) * 2018-12-17 2021-08-16 Lunella Biotech Inc Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas
CA3123850A1 (en) 2018-12-17 2020-06-25 Lunella Biotech, Inc. Triple combination therapies for anti-aging
WO2020242857A1 (en) 2019-05-24 2020-12-03 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
KR20220025849A (ko) * 2019-06-26 2022-03-03 루넬라 바이오테크 인코포레이티드 미토콘드리아의 표적화 및 암 줄기 세포의 근절을 위한 카르보시아닌 화합물
EP4048246B1 (en) * 2019-10-24 2024-07-10 The Medical College of Wisconsin, Inc. Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug
US20230174464A1 (en) * 2020-05-13 2023-06-08 Lunella Biotech, Inc. Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasis
WO2022084947A1 (en) * 2020-10-22 2022-04-28 Lunella Biotech, Inc. Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862921A (en) * 1953-08-13 1958-12-02 Upjohn Co Erythromycin esters
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
AU1411992A (en) * 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
WO1996034852A1 (en) 1995-05-03 1996-11-07 Pfizer, Inc. Novel tetracycline derivatives
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
CN1318434C (zh) 1997-11-25 2007-05-30 安迪珀蒂恩生物工艺学有限公司 线粒体靶向的抗氧剂
DE69919769T2 (de) 1998-03-03 2005-01-27 Pfizer Products Inc., Groton 3,6-Ketal-Makrolidantibiotika
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA04005611A (es) * 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
RU2223103C1 (ru) 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
JP2005200419A (ja) 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
EP1720555A1 (en) 2004-02-26 2006-11-15 Advanced Ocular Systems Limited Tetracycline derivatives for the treatment of ocular pathologies
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
CN1706391A (zh) 2005-05-09 2005-12-14 史同瑞 土霉素混悬乳剂
EP1906948A4 (en) 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
CN1837229A (zh) 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN1837225A (zh) 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
US20080045589A1 (en) 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
JP2009539769A (ja) 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
US20080118432A1 (en) * 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
MX2009004748A (es) 2006-10-30 2009-08-25 Southern Res Inst Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
US20090099062A1 (en) 2007-05-31 2009-04-16 Ethan Lee Pyrvinium For The Treatment of Cancer
US8647673B2 (en) 2007-07-24 2014-02-11 Wayne State University Nanoparticles for imaging and treating chlamydial infection
CA2699794C (en) 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
EP2188630A4 (en) 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
GB0912584D0 (en) 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
MX2012002337A (es) 2009-08-25 2012-06-25 Harvard College Uso de metformina en el tratamiento y prevencion de cancer.
EP2505188A1 (en) * 2009-12-02 2012-10-03 Bettina Heil Suppository for rectal, vaginal or urethral administration
CA2782527C (en) 2009-12-04 2019-09-17 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
US20120329761A1 (en) 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
CN101810570B (zh) * 2010-04-16 2012-06-20 成都师创生物医药科技有限公司 蒽环类抗肿瘤抗生素脂肪酸复合物脂质纳米粒制剂及其制备方法
WO2011133879A2 (en) 2010-04-22 2011-10-27 University Of Massachusetts Combination therapies with mitochondrial-targeted anti-tumor agents
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US10513539B2 (en) 2011-02-10 2019-12-24 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US9801922B2 (en) 2011-08-03 2017-10-31 University Of Iowa Research Foundation Compositions and methods of treating cancer
CN102911226B (zh) * 2011-08-03 2015-11-25 胡梨芳 硬脂酸红霉素类化合物物实体及其用途
US9180134B2 (en) 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
WO2013040206A1 (en) 2011-09-14 2013-03-21 Lewis Thomas J Novel formulations comprising macrolide and tetracycline and their uses
CA2866080C (en) 2012-03-01 2021-01-19 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
US9526795B2 (en) 2012-08-28 2016-12-27 Annam Biosciences, Llc N-BOC-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
CA2898113C (en) 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
WO2014173374A1 (en) 2013-04-24 2014-10-30 Smart Brain s.r.o. Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
JP2016523926A (ja) 2013-07-01 2016-08-12 ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド 抗癌療法のための細胞ミトコンドリアへの治療剤の正確な送達
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
CN103536530A (zh) 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
CA2843943A1 (en) 2014-02-20 2014-05-28 Pankaj Modi Oral formulations of chemotherapeutic agents
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
EP3206674B1 (en) 2014-10-17 2020-03-18 Targeted Therapies Research and Consulting Centre Multi-ingredient pharmaceutical composition for use in cancer therapy
CN104352566A (zh) 2014-10-21 2015-02-18 河南牧翔动物药业有限公司 一种水包油型复方金霉素纳米乳
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
CA2997671A1 (en) 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
CN105884633B (zh) * 2016-05-07 2017-12-26 浙江大学 一种四环素硬脂酸嫁接物及其制备和应用
CN118085109A (zh) 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
CN106511317A (zh) 2016-12-13 2017-03-22 浙江中同科技有限公司 一种掩味克拉霉素颗粒的制备方法
US20190365830A1 (en) 2017-01-18 2019-12-05 Evelo Biosciences, Inc. Methods of treating cancer
EP3570856A2 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
CR20200238A (es) 2017-11-24 2020-12-04 Lunella Biotech Inc Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives

Also Published As

Publication number Publication date
US11160821B2 (en) 2021-11-02
ZA201907654B (en) 2022-07-27
US20220072020A1 (en) 2022-03-10
RU2019142102A3 (es) 2021-06-21
EP3624840A1 (en) 2020-03-25
US20200179424A1 (en) 2020-06-11
PE20200605A1 (es) 2020-03-10
AU2018270129B2 (en) 2021-01-07
KR20200010343A (ko) 2020-01-30
CA3063717A1 (en) 2018-11-22
CN111315400A (zh) 2020-06-19
JP2020527127A (ja) 2020-09-03
CR20190524A (es) 2020-01-10
BR112019024264A2 (pt) 2020-06-02
JP6938682B2 (ja) 2021-09-22
DOP2019000294A (es) 2020-02-16
IL270598B (en) 2022-04-01
PH12019502594A1 (en) 2020-10-26
US11865130B2 (en) 2024-01-09
CA3063717C (en) 2021-08-24
RU2019142102A (ru) 2021-06-21
NZ760422A (en) 2023-11-24
CL2019003283A1 (es) 2020-05-04
EP3624840A4 (en) 2021-03-10
WO2018213751A1 (en) 2018-11-22
MX2019013735A (es) 2020-01-15
AU2018270129A1 (en) 2020-01-16
CO2019012888A2 (es) 2020-05-15
ZA202102509B (en) 2023-03-29
CU20190092A7 (es) 2020-10-20
ZA202202712B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
DOP2019000294A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
ES3063344T3 (en) Cancer treatment using combinations of erk and raf inhibitors
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
PE20200800A1 (es) Composiciones que comprenden derivados de trifenilfosfonio como anticancerigenos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
CO2024008543A2 (es) Composición farmacéutica que comprende un compuesto de quinazolina
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
BR112015014367A2 (pt) formulações inibidoras de lfa-1
MX2018004243A (es) Regimenes de dosificacion.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20200295A1 (es) Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento